ATE400554T1 - 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten - Google Patents

2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten

Info

Publication number
ATE400554T1
ATE400554T1 AT99908933T AT99908933T ATE400554T1 AT E400554 T1 ATE400554 T1 AT E400554T1 AT 99908933 T AT99908933 T AT 99908933T AT 99908933 T AT99908933 T AT 99908933T AT E400554 T1 ATE400554 T1 AT E400554T1
Authority
AT
Austria
Prior art keywords
muscariine
arylethyl
ylmethyl
piperidine
receptor antagonists
Prior art date
Application number
AT99908933T
Other languages
English (en)
Inventor
Joan Caroon
Robin Clark
Michael Dillon
Ralph Harris
Sharathchandra Hegde
Clara Lin
Hans Maag
David Repke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE400554T1 publication Critical patent/ATE400554T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT99908933T 1998-02-27 1999-02-19 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten ATE400554T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7611398P 1998-02-27 1998-02-27
US10909798P 1998-11-19 1998-11-19

Publications (1)

Publication Number Publication Date
ATE400554T1 true ATE400554T1 (de) 2008-07-15

Family

ID=26757679

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99908933T ATE400554T1 (de) 1998-02-27 1999-02-19 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten

Country Status (26)

Country Link
US (1) US6319920B1 (de)
EP (1) EP1058680B1 (de)
JP (1) JP3523198B2 (de)
KR (1) KR100384906B1 (de)
CN (1) CN1143848C (de)
AR (1) AR015523A1 (de)
AT (1) ATE400554T1 (de)
AU (1) AU753255B2 (de)
BR (1) BR9909253A (de)
CA (1) CA2321198C (de)
CO (1) CO4990939A1 (de)
DE (1) DE69939053D1 (de)
ES (1) ES2310032T3 (de)
HR (1) HRP20000544A2 (de)
HU (1) HUP0100760A3 (de)
IL (1) IL137936A0 (de)
MA (1) MA26610A1 (de)
MY (1) MY133445A (de)
NO (1) NO317106B1 (de)
NZ (1) NZ506317A (de)
PE (1) PE20000325A1 (de)
PL (1) PL194037B1 (de)
RU (1) RU2220138C2 (de)
TR (1) TR200002481T2 (de)
WO (1) WO1999043657A1 (de)
YU (1) YU53100A (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2302438A1 (en) * 1997-05-19 1998-11-26 Sugen, Inc. Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
ATE280162T1 (de) 2000-05-25 2004-11-15 Hoffmann La Roche Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
YU88902A (sh) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Supstituisani 1-aminoalkil laktami i njihova primena kao antagonista muskarinskih receptora
BR0214649A (pt) 2001-12-03 2004-11-03 Hoffmann La Roche Derivados de aminotetralina como antagonistas do receptor muscarìnico
WO2003048124A1 (en) 2001-12-03 2003-06-12 F. Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
JP4466370B2 (ja) * 2002-06-07 2010-05-26 アステラス製薬株式会社 過活動膀胱治療剤
BR0215801A (pt) 2002-07-08 2005-05-10 Ranbaxy Lab Ltd Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
KR20050084445A (ko) * 2002-12-20 2005-08-26 다이노젠 파마세우티컬스, 인코포레이티드 α₂δ 서브유닛 칼슘 채널 모듈레이터를 이용한 무통증방광 질환의 치료방법
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1626957A1 (de) 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Azabicycloderivative als muscarinrezeptorantagonisten
WO2005007645A1 (en) * 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
US7214439B2 (en) * 2003-12-19 2007-05-08 Millennium Cell, Inc. Triborohydride salts as hydrogen storage materials and preparation thereof
CN101663270B (zh) 2007-04-24 2013-07-17 施万制药 可用作蕈毒碱受体拮抗剂的季铵化合物
DE102007020492A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
EP3170807B1 (de) * 2015-11-23 2019-12-11 Frau Pharma S.r.l. Neues verfahren zur synthese von fenfluramin
SI25272A (sl) 2016-09-23 2018-03-30 Univerza V Ljubljani Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni
CN112824378A (zh) * 2019-11-20 2021-05-21 珠海润都制药股份有限公司 一种盐酸坦索罗辛的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361791B1 (de) 1988-09-26 1995-11-08 Smithkline Beecham Farmaceutici S.p.A. Azacyclische Verbindungen, verwendbar als Arzneimittel
SU1829346A1 (ru) * 1991-04-01 1996-01-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна ДИГИДРОХЛОРИДЫ N-[β-(1,2,5-ТРИМЕТИЛ-4-АРИЛПИПЕРИДИН-4-ИЛ)ЭТИЛ]-N-АЛКИЛ-N-(3,4-ДИМЕТОКСИБЕНЗИЛ)АМИНОВ, ЯВЛЯЮЩИЕСЯ ИНГИБИТОРАМИ КАЛЬЦИЙ-КАЛЬМОДУЛИНЗАВИСИМЫХ ПРОЦЕССОВ
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
FR2681320B1 (fr) 1991-09-12 1994-01-14 Synthelabo Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2681325B1 (fr) 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
JP3064425B2 (ja) 1995-09-15 2000-07-12 ノイロサーチ アクティーゼルスカブ カルシウムチャンネル・ブロッカーとしてのピペリジン化合物
EP0863141B1 (de) * 1995-10-13 2001-09-12 Banyu Pharmaceutical Co., Ltd. Substituierte heteroaromatische derivate

Also Published As

Publication number Publication date
NZ506317A (en) 2003-08-29
RU2220138C2 (ru) 2003-12-27
EP1058680B1 (de) 2008-07-09
IL137936A0 (en) 2001-10-31
AU753255B2 (en) 2002-10-10
KR100384906B1 (ko) 2003-05-23
EP1058680A1 (de) 2000-12-13
YU53100A (sh) 2003-04-30
CA2321198A1 (en) 1999-09-02
US6319920B1 (en) 2001-11-20
TR200002481T2 (tr) 2000-11-21
MA26610A1 (fr) 2004-12-20
AR015523A1 (es) 2001-05-02
ES2310032T3 (es) 2008-12-16
AU2835399A (en) 1999-09-15
NO20004261D0 (no) 2000-08-25
MY133445A (en) 2007-11-30
WO1999043657A1 (en) 1999-09-02
BR9909253A (pt) 2000-11-28
CN1295563A (zh) 2001-05-16
CN1143848C (zh) 2004-03-31
PE20000325A1 (es) 2000-05-08
NO317106B1 (no) 2004-08-09
KR20010041321A (ko) 2001-05-15
PL342692A1 (en) 2001-07-02
HUP0100760A3 (en) 2002-12-28
CA2321198C (en) 2009-11-17
DE69939053D1 (de) 2008-08-21
HK1036623A1 (en) 2002-01-11
NO20004261L (no) 2000-08-25
CO4990939A1 (es) 2000-12-26
HRP20000544A2 (en) 2001-02-28
JP3523198B2 (ja) 2004-04-26
JP2002504543A (ja) 2002-02-12
PL194037B1 (pl) 2007-04-30
HUP0100760A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
ATE400554T1 (de) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten
DE60023167D1 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
ATE288898T1 (de) Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE280157T1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
FI970107A7 (fi) Heterosyklisiä takykiniinireseptoriantagonisteja
ATE299866T1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
ATE263151T1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
ATE272632T1 (de) Muskarin-rezeptor antagonisten
ATE416173T1 (de) 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4- benzylpiperidine als nmda-rezeptor-antagonisten
ATE286022T1 (de) Naphthalin-carboxamide als tachykinin rezeptorantagonisten
NO20004503L (no) Vitronectin-reseptor-antagonister
NO20016053L (no) IL-8 reseptor-antagonister
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
ATE244716T1 (de) Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten
NO20016052D0 (no) IL-8-reseptor-antagonister
ATE196766T1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten
ATE277043T1 (de) Vitronectin rezeptor antagonist
NO20015775D0 (no) IL-8 reseptorantagonister
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
ATE228514T1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten
NO20015774L (no) IL-8 reseptorantagonister
ATE206421T1 (de) Heterocyclisch substituierte piperazonderivate als tachykinin rezeptor antagonisten
NO20010620D0 (no) Vitronektinreseptor-antagonister

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties